ReviewTranslational andrology and urology2020
Clinical predictive factors in prostatic artery embolization for symptomatic benign prostatic hyperplasia: a comprehensive review.
Review in Translational andrology and urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Pooled it
- Single-center retrospective comparative study of 40-120 μm versus 100-300 μm trisacryl gelatin microspheres as the main embolic agents for prostatic artery embolization.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- Association between magnetic resonance imaging-based prostatic tissue morphology and changes in International Prostate Symptom Score and maximum urinary flow rate after prostatic artery embolization.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- Prostatic artery embolization and imaging-based biomarkers: current tools in monitoring treatment response and emerging strategies.Abdominal radiology (New York) · 2026Review
- Article
- Current considerations in prostate artery embolisation.CVIR endovascular · 2026Article
- Integrated management strategies for benign prostatic hyperplasia.Frontiers in urology · 2025Review
- A correlation study between prostate necrosis rate calculated by 3D Slicer software and clinical efficacy of prostatic artery embolization, along with an analysis of predictors of clinical success after prostatic artery embolization.Abdominal radiology (New York) · 2024Article
- Benefits of Repeat Prostatic Artery Embolization on Persistent or Recurrent Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia.Cardiovascular and interventional radiology · 2023Article
- Influence of benign prostatic hyperplasia patterns detected with MRI on the clinical outcome after prostatic artery embolization.CVIR endovascular · 2023Article
- Prostatic artery occlusion: initial findings on pathophysiological response in a canine prostate model.Translational andrology and urology · 2022Article
- Comprehensive Review on Current Controversies and Debate in Prostate Artery Embolization.Turkish journal of urology · 2022Article
- Minimally Invasive Therapies for Benign Prostatic Obstruction: A Review of Currently Available Techniques Including Prostatic Artery Embolization, Water Vapor Thermal Therapy, Prostatic Urethral Lift, Temporary Implantable Nitinol Device and Aquablation.Cardiovascular and interventional radiology · 2022Review
- Prostatic artery embolization for bladder outlet obstruction in the setting of prior posterior urethroplasty.Urology case reports · 2021Article
- Prostatic artery embolization: magnetic resonance image (MRI) findings in the early detection of prostate infarction in a canine spontaneous benign prostatic hyperplasia model.Translational andrology and urology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostatic artery embolization (PAE) has been established as a routine treatment for symptomatic benign prostatic hyperplasia (BPH) all over the world. With increasing clinical experience in the last decade, investigators have sufficient data to assess predictive factors with the purpose to guide patient selection and counseling for PAE or to individualize therapeutic plans after PAE. This paper is a comprehensive review to introduce the concept of clinical predictors and give a systemic classification of various predictive factors in PAE. The authors review each individual factor and its predictive capability and discuss the possible reasons for the inconsistent or conflicting findings in the literature. Based on current evidence, the baseline prostate volume, in particular the transition zone volume and transition zone index; 24 h post-PAE prostate-specific antigen (PSA) level; and prostate infarction and prostate volume reduction at 1-3 months have potential in prediction of treatment outcomes. Patients with Adenomatous-dominant BPH or with indwelling bladder catheter before PAE may have more benefits from PAE. Baseline intravesical prostatic protrusion (IPP), C-reactive protein (CRP) level at 48 h and early detection of prostate infarct at 1 day and 1 week after PAE need further investigating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.